Whole-body diffusion magnetic resonance imaging in the assessment of lymphoma

Abstract The current evidence regarding the usefulness of whole-body diffusion-weighted magnetic resonance imaging (diffusion MRI) in the assessment of lymphoma is reviewed. Diffusion MRI combining both anatomical and bio-physiological information is currently under investigation as a valuable tool in the oncology field including lymphoma, not only for staging but also for the assessment of response. Representative images for each purpose are shown. Diffusion MRI requires no administration of contrast medium and does not use ionizing radiation, which could be particularly advantageous for repeat follow-up surveillance in lymphoma patients. Diffusion MRI may prove to be a useful biomarker in clinical decision making for patients with lymphoma. Large-scale prospective studies are warranted to further establish its complementary value to the current standard of care, [18F]fluorodeoxyglucose positron emission tomography/computed tomography.

[1]  D. Collins,et al.  Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. , 2011, Radiology.

[2]  T. Takahara,et al.  Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. , 2004, Radiation medicine.

[3]  Dow-Mu Koh,et al.  Practical aspects of assessing tumors using clinical diffusion-weighted imaging in the body. , 2007, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.

[4]  Thomas C. Kwee,et al.  Whole-body diffusion-weighted imaging for staging malignant lymphoma in children , 2010, Pediatric Radiology.

[5]  T. Takahara,et al.  Whole-Body MRI, Including Diffusion-Weighted Imaging, for the Initial Staging of Malignant Lymphoma: Comparison to Computed Tomography , 2009, Investigative radiology.

[6]  Peter R. Luijten,et al.  Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology , 2008, European Radiology.

[7]  M. Sumi,et al.  Diagnostic ability of apparent diffusion coefficients for lymphomas and carcinomas in the pharynx , 2007, European Radiology.

[8]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Pek-Lan Khong,et al.  Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma. , 2011, AJR. American journal of roentgenology.

[11]  Prasun Dastidar,et al.  Diffusion‐weighted MRI in early chemotherapy response evaluation of patients with diffuse large B‐cell lymphoma – a pilot study: comparison with 2‐deoxy‐2‐fluoro‐ D‐glucose‐positron emission tomography/computed tomography , 2011, NMR in biomedicine.

[12]  S. Ng,et al.  Primary Cerebral Lymphoma and Glioblastoma Multiforme: Differences in Diffusion Characteristics Evaluated with Diffusion Tensor Imaging , 2008, American Journal of Neuroradiology.

[13]  Mukesh G Harisinghani,et al.  Current concepts in lymph node imaging. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  A. Bilici,et al.  The role of PET-CT in the differential diagnosis of thymic mass after treatment of patients with lymphoma , 2011, Medical oncology.

[15]  L. Johansson,et al.  Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients , 2011, Acta radiologica.

[16]  Whole-body diffusion-weighted imaging in lymphoma , 2010, Cancer imaging : the official publication of the International Cancer Imaging Society.

[17]  Emmanuel Itti,et al.  Whole-Body Diffusion-Weighted Imaging With Apparent Diffusion Coefficient Mapping for Treatment Response Assessment in Patients With Diffuse Large B-Cell Lymphoma: Pilot Study , 2011, Investigative radiology.

[18]  H. Honda,et al.  Usefulness of the calculated apparent diffusion coefficient value in the differential diagnosis of retroperitoneal masses , 2004, Journal of magnetic resonance imaging : JMRI.

[19]  E. de Vita,et al.  Pediatric and adolescent lymphoma: comparison of whole-body STIR half-Fourier RARE MR imaging with an enhanced PET/CT reference for initial staging. , 2010, Radiology.

[20]  Klemens Scheidhauer,et al.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Babyn,et al.  Initial experience with FSE STIR whole-body MR imaging for staging lymphoma in children , 2004, European Radiology.

[22]  T. Takahara,et al.  Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT. , 2011, AJR. American journal of roentgenology.

[23]  Alexandre Vignaud,et al.  Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma , 2010, European Radiology.